[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"local-recurrence-of-malignant-tumor-of-prostate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:local-recurrence-of-malignant-tumor-of-prostate":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100591595","high-dose-rate-hdr-brachytherapy-salvage-after-prostatectomy-100591595",false,"NCT06982469","High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy","Magnetic Resonance Imaging (MRI)\u002F Positron Emission Tomography (PET) Prostate-specific Membrane Antigen (PSMA) -Based Phase I-II Study of Salvage HDR Brachytherapy and External Beam Irradiation In Isolated Tumor Bed Relapses After Radical Prostatectomy","Inclusion Criteria:\n\n* Patients with increasing PSA after RP and clinical evidence of PET PSMA\u002FCholine+ and MRI+ isolated prostatic bed relapse (IPBR) that is implantable via transperineal route . The IPBR should be visible on TRUS imaging to allow proper implant placement.\n* Pathological confirmation is advised in all cases but it is not mandatory .\n* Brachytherapy MRI-based dosimetry\n* Patient written Informed Consent of the Institutional Review Board-approved protocol that discloses the investigational nature of the treatment as well as the available standard treatment options.\n\nExclusion Criteria:\n\n* Distant Metastases\n* Isolated nodal relapses\n* Prior Irradiation to the IPBR area\n* Multicentric IPBRs\n* Life expectancy of less than 5 years or inability to tolerate and comply with an HDR procedure","MALE","18 Years","80 Years",{"count":20,"type":21},20,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the long-term effects of HDR Brachytherapy in men with isolated local relapses after radical prostatectomy. The main question it aims to answer is:\n\nDoes HDR Brachytherapy increase control rates and decreases complications compared with conventional External Irradiation?\n\nParticipants will be asked to receive HDR brachytherapy as part of their regular medical care for isolated local relapses after radical prostatectomy",[25,26,27,28,29],"Prostate Cancer","Prostatectomy","Local Recurrence of Malignant Tumor of Prostate","Radiotherapy; Complications","Brachytherapy","RECRUITING","2025-06-18",{"date":33,"type":34},"2025-06-19","ACTUAL",{"date":36,"type":34},"2020-05-05",{"date":38,"type":21},"2030-05-01",{"name":40,"class":41},"Clinica Universidad de Navarra, Universidad de Navarra","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100531536","phase-2-stereotactic-re-irradiation-of-local-recurrences-of-prostate-cancer-after-radiotherapy-100531536","NCT06201078","Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy","Phase II Study - Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy - PROSTARE (PROstate Cancer STereotActic REirradiation) Trial","PROSTARE","Inclusion Criteria:\n\n1. Local recurrence of prostate cancer after definitive radiotherapy\n\n   1. biopsy proven or\u002Fand\n   2. Consistent MRI and PET-PSMA results and PSA growth dynamics\n2. Time since primary radiotherapy - at least 2 years\n3. Good performance status (ZUBROD 0-1)\n\n   * If the results of the MRI and PET PSMA are inconsistent, and if there is no technical possibility of performing an MRI biopsy, the treatment is acceptable, but repeated imaging (PET or MRI) should be performed to assess the dynamics of the recurrence.\n\nExclusion Criteria:\n\n1. Polymetastatic dissemination in distant or regional lymph nodes (N1, M1) or oligometastatic dissemination, but not eligible for local forms of metastasis directed therapy (MDT)\n2. Tumour volume (GTV) \\> 14 cc\n3. Poor tolerability of primary radiotherapy (≥G3 toxicity) or persistent late toxicity ≥G2 interfering with re-irradiation\n4. Severe dysuria before repeated SBRT (e.g., IPSS ≥19)\n5. Diseases of the distal part of the rectum or anal canal that may affect SBRT tolerance (e.g., anal fissure)\n6. Previous prostate brachytherapy\n7. Substantial risk for further urologic interventions (e.g., TURB\u002FTURP)",{"count":52,"type":21},55,"INTERVENTIONAL",[55],"PHASE2","The goal of this clinical study is to evaluate the toxicity and efficacy of re-irradiation using focal stereotactic body radiotherapy (SBRT) in patients with local recurrence of prostate cancer after definitive or post-operative radiotherapy.\n\nThe main question is the tolerance of such treatment, concerning the incidence of Grade ≥ 2 and Grade ≥ 3 GU and GI toxicity. Also the efficacy of SBRT will be measured in terms of Biochemical Control with other secondary endpoints which include: Biochemical Response, Biochemical Failure-Free Survival, Metastases-Free Survival, Relapse-Free Survial, Local Control, Overall Survival and patients' reported tolerance measured with Quality of Life questionnaires (QoL C-30 and PR-25).\n\nThe evaluation of the tolerance and effectiveness of stereotactic radiotherapy (SBRT) will be performed in 3 subgroups: in patients with local recurrence after conventionally fractionated\u002Fmoderately hypofractionated definitive radiotherapy (Group A) or ultrahypofractionated definitive SBRT (Group C) or after prostatectomy and post-operative radiotherapy (Group B).\n\nThe study group is planned to include 55 patients.",[27,58],"Radiotherapy",[60,61,62,63],"local recurrence","prostate","radiotherapy","salvage","2025-03-10",{"date":66,"type":34},"2025-03-13",{"date":68,"type":34},"2023-07-31",{"date":70,"type":21},"2029-12-31",{"name":72,"class":41},"Maria Sklodowska-Curie National Research Institute of Oncology"]